Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago

Aprepitant

Anti-emetic drugs Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Nausea and Vomiting Cancer

Vomend is indicated for the prevention of postoperative nausea and vomiting (PONV) and the prevention of chemotherapy-induced nausea and vomiting (CINV).

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Aprepitant is a selective, high affinity antagonist of human substance P neurokinin 1 (NK1) receptors. When substance P attaches to these receptors, it causes nausea and vomiting. Aprepitant stops substance P from binding to the NK1 receptors. By blocking the receptors, Aprepitant can prevent nausea and vomiting, which often happens after chemotherapy or as a complication of surgery.

Pregnancy & Breastfeeding

Pregnancy Category B. This drug should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug based on patient’s importance.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Postoperative nausea and vomiting: the recommended oral dose of aprepitant is 40 mg, taken within 3 hours before induction of anaesthesia. Chemotherapy-induced nausea and vomiting: for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, the following regimen should be used. On Day 1, aprepitant 125 mg orally, dexamethasone 12 mg orally, and a 5-HT3 antagonist (ondansetron) 24 mg given 30 minutes before the start of chemotherapy. On Day 2, aprepitant 80 mg orally and dexamethasone 8 mg orally. On Day 3, aprepitant 80 mg orally and dexamethasone 8 mg orally. On Day 4, dexamethasone 8 mg orally. Aprepitant is given orally 1 hour before chemotherapy on Day 1 and in the morning on Days 2 and 3. Dexamethasone is given 30 minutes before chemotherapy on Day 1 and in the morning on Days 2 through 4. The dexamethasone dose takes drug interactions into account. For the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, the following regimen should be used. On Day 1, aprepitant 125 mg orally, dexamethasone 12 mg orally, and a 5-HT3 antagonist (ondansetron) as one 8 mg tablet 30 minutes before chemotherapy, followed by a further 8 mg dose 8 hours later. On Day 2, aprepitant 80 mg orally and ondansetron 8 mg tablet twice a day. On Day 3, aprepitant 80 mg orally and ondansetron 8 mg tablet twice a day. Aprepitant is given orally 1 hour before chemotherapy on Day 1 and in the morning on Days 2 and 3. Dexamethasone is given 30 minutes before chemotherapy on Day 1. The dexamethasone dose takes drug interactions into account. Aprepitant may be taken with or without food. No dose adjustment is needed for elderly patients.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.